InsiderTrades.com logo
Louise Frederika Kooij net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Louise Kooij Biography and Net Worth

CAO of NewAmsterdam Pharma

Louise Kooij assumed the role of Chief Accounting Officer at NewAmsterdam Pharma in January 2023 after serving as the company’s Chief Financial Officer since May 2020. Before 2016, she worked in different roles with growing responsibility in finance and business. From 2018 to 2020, she was Head of Rare Disease in central and Eastern Europe for Sanofi Genzyme, and from 2016 to 2018, she was responsible for leading the European Business Operations team. Prior to that, she served as Vice President of Business Control and Analysis (Global Scope) in Boston. Louise has more than 25 years of professional experience, 18 of which she spent with Sanofi Genzyme. Prior to that, she worked as a consultant and auditor at PricewaterhouseCoopers and as a Product Group Accountant at Hagemeyer N.V. Louise was involved with major projects such as the integration of Genzyme into Sanofi, reorganizations, and acquisitions. Louise earned her master’s degree from Nyenrode Business University and her auditing degree from Hogeschool Markus Verbeek.

What is Louise Frederika Kooij's net worth?

The estimated net worth of Louise Frederika Kooij is at least $223,500.00 as of March 4th, 2025. Kooij owns 15,000 shares of NewAmsterdam Pharma stock worth more than $223,500 as of April 11th. This net worth estimate does not reflect any other assets that Kooij may own. Learn More about Louise Frederika Kooij's net worth.

How old is Louise Frederika Kooij?

Kooij is currently 48 years old. There are 6 older executives and no younger executives at NewAmsterdam Pharma. The oldest executive at NewAmsterdam Pharma is Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director, who is 70 years old. Learn More on Louise Frederika Kooij's age.

How do I contact Louise Frederika Kooij?

The corporate mailing address for Kooij and other NewAmsterdam Pharma executives is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. NewAmsterdam Pharma can also be reached via phone at 352062971 and via email at max.nowicki@frazierhealthcare.com. Learn More on Louise Frederika Kooij's contact information.

Has Louise Frederika Kooij been buying or selling shares of NewAmsterdam Pharma?

Louise Frederika Kooij has not been actively trading shares of NewAmsterdam Pharma within the last three months. Most recently, Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a transaction totalling $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at $305,550. Learn More on Louise Frederika Kooij's trading history.

Who are NewAmsterdam Pharma's active insiders?

NewAmsterdam Pharma's insider roster includes Juliette Audet (Insider), Michael Davidson (CEO), Johannes Kastelein (Insider), Louise Kooij (CAO), and James Topper (Director). Learn More on NewAmsterdam Pharma's active insiders.

Are insiders buying or selling shares of NewAmsterdam Pharma?

During the last twelve months, NewAmsterdam Pharma insiders bought shares 4 times. They purchased a total of 11,244 shares worth more than $213,344.05. During the last twelve months, insiders at the sold shares 10 times. They sold a total of 641,730 shares worth more than $15,201,594.63. The most recent insider tranaction occured on March, 26th when Director James N Topper bought 1,135 shares worth more than $25,526.15. Insiders at NewAmsterdam Pharma own 19.5% of the company. Learn More about insider trades at NewAmsterdam Pharma.

Information on this page was last updated on 3/26/2025.

Louise Frederika Kooij Insider Trading History at NewAmsterdam Pharma

See Full Table

Louise Frederika Kooij Buying and Selling Activity at NewAmsterdam Pharma

This chart shows Louise Frederika Kooij's buying and selling at NewAmsterdam Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M$0$2MTotal Insider BuyingTotal Insider Selling

NewAmsterdam Pharma Company Overview

NewAmsterdam Pharma logo
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Read More

Today's Range

Now: $14.90
Low: $14.41
High: $15.79

50 Day Range

MA: $20.38
Low: $14.90
High: $24.07

2 Week Range

Now: $14.90
Low: $14.06
High: $27.29

Volume

602,588 shs

Average Volume

578,663 shs

Market Capitalization

$1.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A